



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 464 335 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

06.10.2004 Bulletin 2004/41

(51) Int Cl.7: A61K 31/4709, C07D 401/12,

C07D 403/12, C07D 405/12,

C07D 409/12, C07D 413/12,

C07D 417/12, C07D 417/14,

C07D 215/38, A61K 31/506,

A61P 3/04

(21) Application number: 04007651.5

(22) Date of filing: 30.03.2004

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated Extension States:

AL LT LV MK

(30) Priority: 31.03.2003 US 458530 P

19.08.2003 US 495911 P

09.10.2003 US 510186 P

16.12.2003 US 530360 P

• Omodera, Katsunori

Taisho Pharmaceutical Co. Ltd

Tokyo (JP)

• Busujima, Tsuyoshi

Taisho Pharmaceutical Co. Ltd

Tokyo (JP)

• Tran, Thuy-Anh

San Diego CA 92130 (US)

• Han, Sangdon

San Diego CA 92127 (US)

• Casper, Martin

San Diego CA 92130 (US)

• Kramer, Bryan A.

San Diego Ca 92126 (US)

• Semple, Graeme

San Diego CA 92127 (US)

• Zou, Ning

San Diego CA 92127 (US)

(71) Applicants:

• Taisho Pharmaceutical Co. Ltd.
Tokyo (JP)• Arena Pharmaceuticals, Inc.
San Diego, CA 92121 (US)

(72) Inventors:

• Sekiguchi, Yoshinori
Taisho Pharmaceutical Co. Ltd

Tokyo (JP)

• Kanuma, Kosuke Taisho Pharmaceutical Co. Ltd
Tokyo (JP)

(74) Representative: HOFFMANN - EITLE


Patent- und Rechtsanwälte

Arabellastrasse 4

81925 München (DE)

(54) QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST

(57) The present invention relates to compounds of the Formula (I)



wherein Q is: